Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ad5 nCOV - Tianjin CanSino Biotechnology

Drug Profile

Ad5 nCOV - Tianjin CanSino Biotechnology

Alternative Names: Ad5-nCOV - Tianjin CanSino Biotechnology; COVID-19 vaccine - Tianjin CanSino Biotechnology; Recombinant Coronavirus Vaccine - Tianjin CanSino Biotechnology; Recomboinant novel coronavirus vaccine - Tianjin CanSino Biotechnology

Latest Information Update: 23 Jun 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tianjin CanSino Biotechnology
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II COVID 2019 infections

Most Recent Events

  • 28 May 2020 CanSino Biotechnology plans a phase I/II trial in Healthy volunteers (In adults, In elderly) in Canada (IM) (NCT04398147)
  • 14 May 2020 The National Research Council (NRC) of Canada and Tianjin CanSino Biotechnology continue collaboration for clinical development of Ad5 nCOV for COVID-2019 infections in Canada
  • 12 May 2020 Tianjin CanSino Biotechnology plans to file CTA to Health Canada for COVID-2019 infections
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top